Journal of Translational Medicine · 2010 · 254 citations · 26 references
MedicineImmunologyPharmacologyCancer ImmunologyImmunotherapyTumor ImmunologyBreast Cancer PharmacotherapyCancer ImmunotherapyCombination ImmunotherapyImmunotherapy For Breast CancerMetastatic Breast CancerTumor-associated AntigensBreast Cancer ChemotherapyCd8 Positive T Cell ResponsesCd8 T Cell ActivationCombination ChemoimmunotherapyMemory T Cell Responses To TumorsMetastatic Breast Cancer TreatmentMhc Class Ii MoleculesRecombinant Fusion Proteins
BACKGROUND: IMP321 is a recombinant soluble LAG-3Ig fusion protein that binds to MHC class II with high avidity and mediates APC and then antigen-experienced memory CD8+ T cell activation. We report clinical and biological results of a phase I/II in patients with metastatic breast carcinoma (MBC) receiving first-line paclitaxel weekly, 3 weeks out of 4. METHODS: MBC patients were administered one dose of IMP321 s.c. every two weeks for a total of 24 weeks (12 injections). The repeated single doses were administered the day after chemotherapy at D2 and D16 of the 28-day cycles of paclitaxel (80 mg/m2 at D1, D8 and D15, for 6 cycles). Blood samples were taken 13 days after the sixth and the twelfth IMP321 injections to determine sustained APC, NK and memory CD8 T cell responses. RESULTS: Thirty MBC patients received IMP321 in three cohorts (doses: 0.25, 1.25 and 6.25 mg). IMP321 induced both a sustained increase in the number and activation of APC (monocytes and dendritic cells) and an increase in the percentage of NK and long-lived cytotoxic effector-memory CD8 T cells. Clinical benefit was observed for 90% of patients with only 3 progressors at 6 months. Also, the objective tumor response rate of 50% compared favorably to the 25% rate reported in the historical control group. CONCLUSIONS: The absence of toxicity and the demonstration of activity strongly support the future development of this agent for clinical use in combined first-line regimens. TRIAL REGISTRATION: ClinicalTrials.gov NCT00349934.
26
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Kathy D. Miller, Molin Wang, Julie R. Gralow et al. · New England Journal of Medicine · 2007 · 3.1K citations · Full text
Medicine, Oncology, Pharmacology +13
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Noëlia Casares, Marie O. Péquignot, Antoine Tesnière et al. · The Journal of Experimental Medicine · 2005 · 1.5K citations · Full text
Medicine, Immunology, Oncology +17
Immunogenic death of colon cancer cells treated with oxaliplatin
Antoine Tesnière, F. Schlemmer, Valérie Boige et al. · Oncogene · 2009 · 1.1K citations
Medicine, Oncology, Pharmacology +14